Table 2. Characteristics of included studies.

Study	n	Patient-centered outcome	Intervention (dose) (n) [mean age, y]	Control group (dose) (n) [mean age, y]	Length of study, treatment regimen
Ziagham et al. [27] (2012)	40	CSVS Max = 12, higher scores reflect more severe symptoms	Vaginal vitamin E (1 mg/2.22 IU) (n = 20) [54.9 ± 4.38]	Vaginal hyaluronic acid (5 mg) (n = 20) [54 ± 5.16]	8 weeks Weeks 1–2: daily Weeks 3–8: every other day
Ziagham et al. [23] (2013)	42	CSVS Max score = 12, higher score reflect more severe symptoms	Vaginal vitamin E (1 mg/2.22 IU) (n = 20) [54.9 ± 5.16]	Placebo: semi-synthetic fatty acid TG (n = 22) [53.77 ± 5.3]	8 weeks Weeks 1–2: daily Weeks 3–8: every other day
Golmakani et al. [28] (2019)	52	ASFQ Max score = 36, higher scores reflect better sexual function	Vaginal vitamin E (100 IU) (n = 26) [unavailable]	Conjugated vaginal estrogen cream (0.5 g) (n = 26) [unavailable]	12 weeks Weeks 1–2: daily Weeks 3–12: twice weekly
Parnan Emamverdikhan et al. [29] (2014)	52	MEQOL Higher scores reflect lower quality of life	Vaginal vitamin E (100 IU) (n = 26) [52.11 ± 4.70]	Conjugated vaginal estrogen cream (0.5 g) (n = 26) [52.88 ± 6.30]	12 weeks Weeks 1–2: daily Weeks 3–12: twice weekly

CSVS: Composite Score of Vaginal Symptoms, ASFQ: Abbreviated Sexual Function Questionnaire, MEQOL: Menopause-Specific Quality of Life.